CDKN2A and gastric cancer: Inspired by the former studies demonstrating that the low cyclin‐dependent kinase inhibitor 2A (CDKN2A) expression in EBV‐associated gastric tumorigenesis [6], we recently explored the potential connection between the genomic and expression alteration of CDKN2A and the EBV infection status in gastric cancer and obtained several thought‐provoking results.